JAK2 and myeloproliferative neoplasm: Published studies have shown that MPN cells display certain immune checkpoint molecules, including PD‐L1, which may contribute to resistance, and that constitutive activation of JAK2 by the V617F mutation causes PD‐L1 upregulation in MPN cells.14, 15